Sarah Aiosa – SVP & President Latin America, MSD
Sarah Aiosa, SVP and President of MSD (known as Merck & Co. in the U.S. and Canada) for Latin America, highlights nearly four years of strong growth built on a…
Loeffler SA de CV is a Mexican company that began its activities in 2000, with the development of human pharmaceuticals products for the generics market.
Their generic pharmaceutical products are manufactured under strict quality standards; having the same properties as an innovative product.
The key to success that has distinguished Loeffler is its investment and edge technology in order to be able to get the most competitive, reliable and affordable products in the pharmaceutical field.
Contact Details
Calzada de las Armas No. 110, Fracc. Ind. las Armas
CP 11210, México DF
MEXICO
Tel: +52 (55) 2626 9100
Website: www.loeffler.com.mx
Sarah Aiosa, SVP and President of MSD (known as Merck & Co. in the U.S. and Canada) for Latin America, highlights nearly four years of strong growth built on a…
Pharmaceutical innovators are sounding the alarm on Mexico’s healthcare reforms, despite the government’s bold claims. At industry group AMIIF’s 75th anniversary, Health Secretary David Kershenobich hailed the Sheinbaum administration’s investments…
In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract…
Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent…
In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms…
Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an…
This interview explores Esmeralda Ortiz’s transformative leadership at Grupo Loeffler Russek (GLR), where she has worked to professionalize operations, strengthen the product portfolio, and position the company for sustainable growth.…
Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical…
See our Cookie Privacy Policy Here
